Dr. Soliman Abdel Kader Fakeeh Hospital (4017) Stock Overview
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4017 from our risk checks.
4017 Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Dr. Soliman Abdel Kader Fakeeh Hospital Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س36.96 |
| 52 Week High | ر.س43.30 |
| 52 Week Low | ر.س27.20 |
| Beta | 0 |
| 1 Month Change | 7.50% |
| 3 Month Change | 19.23% |
| 1 Year Change | -12.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.61% |
Recent News & Updates
Dr. Soliman Abdel Kader Fakeeh Hospital (TADAWUL:4017) Will Be Hoping To Turn Its Returns On Capital Around
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Earnings Not Telling The Story For Dr. Soliman Abdel Kader Fakeeh Hospital Company (TADAWUL:4017)
Dr. Soliman Abdel Kader Fakeeh Hospital Company's ( TADAWUL:4017 ) price-to-earnings (or "P/E") ratio of 28.4x might...Recent updates
Shareholder Returns
| 4017 | SA Healthcare | SA Market | |
|---|---|---|---|
| 7D | 2.7% | -0.5% | -1.7% |
| 1Y | -12.5% | -17.1% | 5.8% |
Return vs Industry: 4017 exceeded the SA Healthcare industry which returned -16.2% over the past year.
Return vs Market: 4017 underperformed the SA Market which returned 6.1% over the past year.
Price Volatility
| 4017 volatility | |
|---|---|
| 4017 Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 5.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in SA Market | 7.8% |
| 10% least volatile stocks in SA Market | 2.7% |
Stable Share Price: 4017 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4017's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | n/a | Mazen Soliman Abdel Fakeeh | dsfhjeddah.fakeeh.care |
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services.
Dr. Soliman Abdel Kader Fakeeh Hospital Company Fundamentals Summary
| 4017 fundamental statistics | |
|---|---|
| Market cap | ر.س8.43b |
| Earnings (TTM) | ر.س256.39m |
| Revenue (TTM) | ر.س3.11b |
Is 4017 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4017 income statement (TTM) | |
|---|---|
| Revenue | ر.س3.11b |
| Cost of Revenue | ر.س2.45b |
| Gross Profit | ر.س663.12m |
| Other Expenses | ر.س406.73m |
| Earnings | ر.س256.39m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 21.30% |
| Net Profit Margin | 8.24% |
| Debt/Equity Ratio | 17.6% |
How did 4017 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 10:01 |
| End of Day Share Price | 2026/06/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Soliman Abdel Kader Fakeeh Hospital Company is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jassim Al-Jubran | Aljazira Capital Company |
| Marina Mikhail | CI Capital Research |
| Ahmed Moataz | EFG-Hermes Research |